



5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al..

Serial No.: 09/559,764 ✓

Group Art Unit: 1644 ✓

Filed: April 27, 2000

Examiner: J. Roark

For: INHIBITION OF BRADYKININ RELEASE

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Mail Stop _____
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Communication dated June 6, 2003
2. Signed Response to Office Action dated September 6, 2003

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop _____
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 7, 2003.

Cheryl H. Agris
(name of person mailing paper)

Cheryl H. Agris
(signature of person mailing paper)



Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

RESPONSE TO COMMUNICATION


Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the communication dated June 6, 2003, Applicants herewith submit a signed copy of the response as filed on March 6, 2003.

Respectfully submitted,

Date: July 7, 2003


Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, New Jersey 08740



Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated September 6, 2003, please consider the following amendments and remarks.

IN THE SPECIFICATION

Please amend the specification as follows, with a marked up version attached hereto:

Please amend the paragraph on page 10, lines 10-13 to read as follows:

Figures 5A and 5B shows inhibition of bradykinin- and HBP-induced increase in EC permeability with monoclonal antibody MBK3 to bradykinin. Bradykinin (100 nM; Figure 5a) or HBP (75 µg/ml; Figure 5b) is administered at time zero to the lamina side of EC monolayers pre-incubated with mAb MBK3 (40 µg/ml).

Please amend the paragraph on page 11, lines 2-6 to read as follows:

Figures 11 A-C show Saturation of native HBP, [R23S,F25E]HBP, and [G175Q]HBP